Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds William Blair Downgrades Actinium Pharmaceuticals to Market Perform

William Blair Downgrades Actinium Pharmaceuticals to Market Perform

William Blair analyst Andy Hsieh downgrades Actinium Pharmaceuticals (AMEX:ATNM) from Outperform to Market Perform.

byBenzinga Newsdesk

February 21, 2023

1 minute read

William Blair analyst Andy Hsieh downgrades Actinium Pharmaceuticals (AMEX:ATNM) from Outperform to Market Perform.

Jefferies Downgrades TCR2 Therapeutics to Underperform, Lowers Price Target to $3

By Benzinga Newsdesk

March 9, 6:57 AM

Jefferies analyst Kelly Shi downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Underperform and lowers the price target from $18 to $3.

TCRR

Analyst Ratings

12 Analysts Have This to Say About Intellia Therapeutics

By Benzinga Insights

May 5, 5:00 PM

Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

NTLA

News

‘Tesla Opens Order Page in Taiwan for Giga Berlin-Made Model Y’ -Tesmanian Report

By Benzinga Newsdesk

September 23, 9:54 AM

https://www.tesmanian.com/blogs/tesmanian-blog/tesla-opens-order-page-for-made-in-giga-berlin-model-y-in-taiwan

TSLA

M&A
News

SeaSpine Says Orthofix Medical Board Unanimously Determined SeaSpine Merger Transaction Continues To Be In Best Interest Of Orthofix, Co.’s Shareholders

By Michael Horton

November 30, 6:37 PM

-SEC Filing

OFIX

William Blair Downgrades Actinium Pharmaceuticals to Market Perform

Related Posts

Jefferies Downgrades TCR2 Therapeutics to Underperform, Lowers Price Target to $3

12 Analysts Have This to Say About Intellia Therapeutics

‘Tesla Opens Order Page in Taiwan for Giga Berlin-Made Model Y’ -Tesmanian Report

SeaSpine Says Orthofix Medical Board Unanimously Determined SeaSpine Merger Transaction Continues To Be In Best Interest Of Orthofix, Co.’s Shareholders